Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Mereo Biopharma Group Plc ( (MREO) ) just unveiled an update.
On May 13, 2025, Mereo BioPharma Group plc held its Annual General Meeting where all proposed resolutions were passed except for Resolution 6. Key resolutions included the adoption of the company’s annual report, re-appointment of PwC as auditors, and approval of the directors’ remuneration report. The board decided that advisory votes on executive compensation will occur annually until 2031. Shareholders also re-elected directors Dr. Deepika Pakianathan, Dr. Pierre Jacquet, and Michael Wyzga.
The most recent analyst rating on (MREO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Mereo Biopharma Group Plc stock, see the MREO Stock Forecast page.
Spark’s Take on MREO Stock
According to Spark, TipRanks’ AI Analyst, MREO is a Neutral.
Mereo Biopharma Group’s overall stock score reflects significant financial and operational challenges typical of an early-stage biotech firm. The lack of revenue and ongoing cash flow issues weigh heavily on its financial performance. Technical indicators suggest some bearish momentum, although not excessively so. The valuation remains unattractive with a negative P/E ratio and no dividends, indicating limited immediate returns for investors.
To see Spark’s full report on MREO stock, click here.
More about Mereo Biopharma Group Plc
Average Trading Volume: 1,549,517
Technical Sentiment Signal: Sell
Current Market Cap: $387.9M
Learn more about MREO stock on TipRanks’ Stock Analysis page.